Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY:JNJ)

155.85 -1.84 (-1.17%)
Streaming Delayed Price Updated: 10:16 AM EDT, Jul 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
2 Dividend Stocks to Buy and Never Sell
Via The Motley Fool
Topics Lawsuit
Peering Into Johnson & Johnson's Recent Short Interest
Via Benzinga
Johnson & Johnson’s Q1 Earnings Call: Our Top 5 Analyst Questions
Johnson & Johnson’s first quarter results reflected a steady performance, with the company surpassing Wall Street’s revenue and adjusted profit expectations. Management credited the diversified... 
Via StockStory
Topics Earnings World Trade
Elizabeth Warren, Jan Schakowsky Reportedly Seek Answers From Pfizer, Amgen, And Others On Low Federal Tax Bills
The Democratic lawmakers alleged that pharmaceutical companies avoided paying U.S. tax bills by shifting their profits to offshore subsidiaries in jurisdictions with significantly lower tax rates, such... 
Via Stocktwits
Topics Government
12 Analysts Have This To Say About Johnson & Johnson
Via Benzinga
P/E Ratio Insights for Johnson & Johnson
Via Benzinga
Johnson & Johnson (NYSE:JNJ) - A Reliable Dividend Stock Worth Considering
Johnson & Johnson (NYSE:JNJ) is a top dividend stock with a 3.32% yield, strong profitability, and a reliable payout history, making it a solid choice for income investors. 
Via Chartmill
Should You Forget Johnson & Johnson and Buy This Magnificent High-Yield Stock Instead?
Via The Motley Fool
Topics Lawsuit
If I Could Invest $1,000 in Any Growth Stock, It Would Be This One
Via The Motley Fool
Topics Artificial Intelligence Economy Government
5 Unstoppable Dividend Stocks to Buy If There's a Stock Market Sell-Off
Steady growth and dividend increases over decades can make investors remarkably wealthy. 
Via The Motley Fool
Topics Economy
Johnson & Johnson Elects Daniel Pinto, President, JPMorganChase to its Board of Directors
From Johnson & Johnson
Via Business Wire
Rep. Gilbert Ray Cisneros Has Bought Up to $410K Worth Of Johnson & Johnson Stock: Here's What You Should Know
Via Benzinga
3 Top Dividend Stocks Analysts Are Bullish on Right Now
With earnings season coming to an end, investors are looking for new catalysts; here are three blue-chip companies with strong analyst support 
Via MarketBeat
Topics ETFs
Dr Reddy's And Alvotech Join Hands To Develop Biosimilar For Merck's Blockbuster Cancer Drug
Alvotech and Dr. Reddy's will co-develop a biosimilar to Keytruda, aiming to expand global access to cancer treatment alternatives. 
Via Benzinga
AnaptysBio's Arthritis Drug Matches Top Therapies In Phase 2 Trial, Analyst Sees Turning Point
Rosnilimab met key RA trial goals, with sustained clinical responses and safety benefits, prompting an analyst upgrade and price target hike to $38. 
Via Benzinga
Johnson & Johnson Highlights Multiple Blood Cancer Trial Data At ASCO Presentation
Johnson & Johnson shared positive ASCO 2025 results, including improved survival and remission in prostate and multiple myeloma patients. 
Via Benzinga
5 Cheap Stocks to Buy in June
These stocks are ready for a summer surge. 
Via The Motley Fool
Top 3 Reasons Savvy Investors Are Buying Johnson & Johnson Stock While Others Panic Over Lawsuits
For long-term investors looking for both stability and innovation in the healthcare space, JNJ is a rare combination of both. 
Via Talk Markets
Michael Mahoney Turned Boston Scientific Into A Medical Tech Empire
Michael Mahoney's grandfather was a cardiac surgeon — so his first career plan was to become a doctor. Mahoney didn't give up — he adjusted. 
Via Investor's Business Daily
3 Elite High-Yield Dividend Stocks Down 8% to 27% That Have Hiked Their Payouts for More than 50 Years in a Row
Via The Motley Fool
Topics Bonds
Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results
From Johnson & Johnson
Via Business Wire
Why Is Teva Stock Trading Higher On Tuesday?
Teva starts IND-enabling studies for BD9, a dual-target therapy for asthma and atopic dermatitis, under license from Biolojic Design. 
Via Benzinga
Why Dan Loeb Just Made Kenvue One Of His Top Holdings
Activist investor Dan Loeb's Third Point LLC acquired a significant stake in consumer health company Kenvue Inc. in Q1 2025. 
Via Benzinga
1 Top Dividend Stock to Buy for a Lifetime of Passive Income
Via The Motley Fool
Topics Economy Lawsuit
Johnson & Johnson (NYSE:JNJ) – A Reliable Dividend Stock Worth Considering
Johnson & Johnson (NYSE:JNJ) offers a strong dividend yield, consistent growth, and solid profitability, making it a compelling choice for income investors. 
Via Chartmill
Investing for Passive Income? Here's What History Says About the Stability of Dividend King Stocks.
Via The Motley Fool
Generating Passive Income: 3 Top Dow Dividend Stocks to Buy for 2025 and Beyond
Via The Motley Fool
Topics Bonds Stocks
Elon Musk Commits to Tesla. Is That a Good Thing?
Via The Motley Fool
Value Investing Is Not Dead - It Just Got Smarter
Via Benzinga
FDA Panel Reiterates the Cancer Risks of Talc
From Beasley Allen Law Firm
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.